In vitro experiments demonstrated that targeted inhibition of TREM1 not only exerted anti-tumor effects but also suppressed the PMT process in GBM and inhibited the activation of the TLR4/PI3K/AKT/mTOR signaling axis, further highlighting its clinical significance in GBM progression. Here, TLR4 is linked to glioblastoma.